Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments.

An N-terminal dopamine D(2s) receptor clone was constructed and coexpressed in COS-7 cells together with a separate gene fragment coding for the C-terminal sequence of the dopamine D(2s) receptor. The truncated receptor (referred to as D(2trunc)) contained transmembrane domains I-V and the N-terminal portion of the third cytoplasmic loop, whereas the C-terminal receptor fragment (referred to as D(2tail)) contained transmembrane domains VI and VII and the adjacent intra- and extracellular sequences of the dopamine D(2s) receptor. Expression in COS-7 cells of either of these two polypeptides alone did not result in any detectable [3H]methylspiperone binding activity. However, specific [3H]methylspiperone binding could be observed after coexpression of the D(2trunc) and D(2tail) gene constructs; the number of receptors present on the plasma membrane was about 10% with respect to that of the wild type. The binding properties of the coexpressed fragments were similar to those of the wild-type dopamine D(2s) receptor for agonists and antagonists. Functional stimulation of the cotransfected D(2trunc) and D(2tail) fragments with quinpirole resulted in the inhibition of adenylate cyclase activity. Maximal inhibition corresponds to a 28% decrease in forskolin-stimulated adenylate cyclase. The apparent IC(50) of quinpirole was 5.1+/-0.3 mcM. These findings confirm and extend analogous data for other G protein-coupled receptors and indicate that this phenomenon is of general importance for the entire family of these proteins.

[1]  S. S. Lee,et al.  In vivo assembly of rhodopsin from expressed polypeptide fragments. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Grandy,et al.  Cloning of the cDNA and gene for a human D2 dopamine receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Gerfen,et al.  Multiple D2 dopamine receptors produced by alternative RNA splicing , 1989, Nature.

[4]  J. Wess,et al.  Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co‐expressed receptor polypeptide. , 1996, The EMBO journal.

[5]  T. Schwartz,et al.  Split-receptors in the tachykinin neurokinin-1 system--mutational analysis of intracellular loop 3. , 1998, European journal of biochemistry.

[6]  C. Londos,et al.  A highly sensitive adenylate cyclase assay. , 1974, Analytical biochemistry.

[7]  M. Caron,et al.  Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. , 1988, Science.

[8]  Jie Liu,et al.  Plasma Membrane Localization and Functional Rescue of Truncated Forms of a G Protein-coupled Receptor (*) , 1995, The Journal of Biological Chemistry.

[9]  D. Engelman,et al.  Membrane protein folding and oligomerization: the two-stage model. , 1990, Biochemistry.

[10]  J. Wess,et al.  Molecular Mechanisms Involved in Muscarinic Acetylcholine Receptor-mediated G Protein Activation Studied by Insertion Mutagenesis (*) , 1996, The Journal of Biological Chemistry.

[11]  C Higgs,et al.  Domain swapping in G-protein coupled receptor dimers. , 1998, Protein engineering.

[12]  P. Seeman,et al.  Dopamine D2 receptor dimers and receptor-blocking peptides. , 1996, Biochemical and biophysical research communications.

[13]  B. Cullen Use of eukaryotic expression technology in the functional analysis of cloned genes. , 1987, Methods in enzymology.

[14]  B. Sommer,et al.  The dopamine D2 receptor: two molecular forms generated by alternative splicing. , 1989, The EMBO journal.

[15]  G. Demontis,et al.  G protein-linked receptors: pharmacological evidence for the formation of heterodimers. , 1999, The Journal of pharmacology and experimental therapeutics.

[16]  P. Sokoloff,et al.  Novel dopamine receptors half a decade later. , 1995, Trends in pharmacological sciences.

[17]  R. Todd,et al.  Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. , 1994, The Journal of pharmacology and experimental therapeutics.

[18]  C. Reynolds,et al.  A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors. , 1997, Journal of medicinal chemistry.

[19]  P. Sokoloff,et al.  Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. , 1999, European journal of pharmacology.

[20]  P. Seeman,et al.  Dopamine D2 receptor dimers in human and rat brain , 1998, FEBS letters.

[21]  M. Martres,et al.  Alternative splicing directs the expression of two D2 dopamine receptor isoforms , 1989, Nature.

[22]  J. Wess,et al.  Reconstitution of functional muscarinic receptors by co‐expression of amino‐ and carboxyl‐terminal receptor fragments , 1993, FEBS letters.